eligibility_summary
Eligible: adults (≥18) with histologically confirmed relapsed/refractory DLBCL who received at least one dose of tafasitamab plus lenalidomide via the Named Patient Program (D.M. 7 Sep 2017) between Apr–Dec 2022 and provided consent (if required). Exclude patients who received the same regimen within a clinical trial.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Italian multicenter retrospective observational study of R/R DLBCL patients previously treated (standard care, named-patient program) with tafasitamab plus lenalidomide. Drugs/mechanisms: Tafasitamab is a humanized, Fc‑engineered anti‑CD19 monoclonal antibody (IgG1) that targets CD19 on B cells and mediates tumor killing via ADCC, ADCP, and direct pro‑apoptotic signaling. Lenalidomide is an oral immunomodulatory drug (IMiD) that binds cereblon, driving IKZF1/IKZF3 degradation, it enhances NK- and T‑cell activation, cytokine production, and synergizes by boosting ADCC and exerting antiproliferative effects (e.g., IRF4/MYC downregulation). Cells/pathways targeted: CD19+ malignant B cells (B‑cell receptor co‑receptor pathway), innate (NK) and adaptive (T‑cell) immune effector pathways via cereblon/IKZF modulation. The study assesses real‑world effectiveness and safety.